ArticleEBioMedicine2015
The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.
Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Identification and analysis of endoplasmic reticulum stress-related genes in neuroblastoma and construction of a prognostic gene signature.Translational cancer research · 2026Article
- Identification of novel biomarkers and prognostic model for neuroblastoma using Mendelian randomization and transcriptomic analysis.Discover oncology · 2025Article
- Mutually exclusive teams-like patterns of gene regulation characterize phenotypic heterogeneity along the noradrenergic-mesenchymal axis in neuroblastoma.Cancer biology & therapy · 2024Article
- Kinases Controlling Stability of the Oncogenic MYCN Protein.ACS medicinal chemistry letters · 2023Article
- Review
- Review
- TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma.BMC genomic data · 2022Article
- Identification of hub genes and their correlation with infiltration of immune cells inFrontiers in immunology · 2022Article
- Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells.Cancers · 2021Article
- CD146 is a potential immunotarget for neuroblastoma.Cancer science · 2021Article
- A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.Oncogene · 2021Article
- Review
- Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities inInternational journal of molecular sciences · 2021Article
- Analysis and identification of novel biomarkers involved in neuroblastoma via integrated bioinformatics.Investigational new drugs · 2021Article
- Targeting Non-Oncogene Addiction for Cancer Therapy.Biomolecules · 2021Review
- Integration of gene expression data identifies key genes and pathways in colorectal cancer.Medical oncology (Northwood, London, England) · 2021Article
- Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival.Journal of applied statistics · 2021Article
- Article
- MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.Oncotarget · 2020Article
- Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma.Frontiers in oncology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Dysregulated expression of MYC family genes is a hallmark of many malignancies. Unfortunately, these proteins are not amenable to blockade by small molecules or protein-based therapeutic agents. Therefore, we must find alternative approaches to target MYC-driven cancers. Amplification of MYCN, a MYC family member, predicts high-risk neuroblastoma (NB) disease. We have shown that R9-caPep blocks the interaction of PCNA with its binding partners and selectively kills human NB cells, especially those with MYCN amplification, and we now show the mechanism. We found elevated levels of DNA replication stress in MYCN-amplified NB cells. R9-caPep exacerbated DNA replication stress in MYCN-amplified NB cells and NB cells with an augmented level of MYC by interfering with DNA replication fork extension, leading to Chk1 dependence and susceptibility to Chk1 inhibition. We describe how these effects may be exploited for treating NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.